
## Laia Bruni

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9068826/publications.pdf Version: 2024-02-01



LAIA ROUNI

#	Article	IF	CITATIONS
1	TIPICO X: report of the 10th interactive infectious disease workshop on infectious diseases and vaccines. Human Vaccines and Immunotherapeutics, 2021, 17, 759-772.	3.3	1
2	HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010–2019. Preventive Medicine, 2021, 144, 106399.	3.4	329
3	A proposed new generation of evidence-based microsimulation models to inform global control of cervical cancer. Preventive Medicine, 2021, 144, 106438.	3.4	20
4	Determinants of Human Papillomavirus Vaccine Uptake by Adult Women Attending Cervical Cancer Screening in 9 European Countries. American Journal of Preventive Medicine, 2021, 60, 478-487.	3.0	13
5	Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. The Lancet Clobal Health, 2020, 8, e191-e203.	6.3	2,111
6	Prevalence and genotype distribution of cervical human papilomavirus infection in the pre-vaccination era: a population-based study in the Canary Islands. BMJ Open, 2020, 10, e037402.	1.9	7
7	Long-term protection of HPV test in women at risk of cervical cancer. PLoS ONE, 2020, 15, e0237988.	2.5	5
8	Is It Now the Time to Plan for Global Gender-Neutral HPV Vaccination?. Journal of Infectious Diseases, 2020, 222, 888-889.	4.0	7
9	Impact of a single-age cohort human papillomavirus vaccination strategy in Catalonia, Spain: Population-based analysis of anogenital warts in men and women. Preventive Medicine, 2020, 138, 106166.	3.4	4
10	Population-level impact of human papillomavirus vaccination. Lancet, The, 2020, 395, 411-412.	13.7	3
11	Long-term protection of HPV test in women at risk of cervical cancer. , 2020, 15, e0237988.		0
12	Long-term protection of HPV test in women at risk of cervical cancer. , 2020, 15, e0237988.		0
13	Long-term protection of HPV test in women at risk of cervical cancer. , 2020, 15, e0237988.		0
14	Long-term protection of HPV test in women at risk of cervical cancer. , 2020, 15, e0237988.		0
15	Human papillomavirus vaccine disease impact beyond expectations. Current Opinion in Virology, 2019, 39, 16-22.	5.4	38
16	Burden of Human papillomavirus (HPV)-related disease and potential impact of HPV vaccines in the Republic of Korea. Papillomavirus Research (Amsterdam, Netherlands), 2019, 7, 26-42.	4.5	15
17	Might Oral Human Papillomavirus (HPV) Infection in Healthy Individuals Explain Differences in HPV-Attributable Fractions in Oropharyngeal Cancer? A Systematic Review and Meta-analysis. Journal of Infectious Diseases, 2019, 219, 1574-1585.	4.0	30
18	Epidemiology and burden of HPV-related disease. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2018, 47, 14-26.	2.8	323

Laia Bruni

#	Article	lF	CITATIONS
19	Population-based e-records to evaluate HPV triage of screen-detected atypical squamous cervical lesions in Catalonia, Spain, 2010–15. PLoS ONE, 2018, 13, e0207812.	2.5	2
20	HPV vaccine implementation and monitoring in Latin America. Salud Publica De Mexico, 2018, 60, 683.	0.4	21
21	Present challenges in cervical cancer prevention: Answers from cost-effectiveness analyses. Reports of Practical Oncology and Radiotherapy, 2018, 23, 484-494.	0.6	9
22	Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. The Lancet Global Health, 2016, 4, e453-e463.	6.3	580
23	Multipurpose prevention technologies for sexual and reproductive health: mapping global needs for introduction of new preventive products. Contraception, 2016, 93, 32-43.	1.5	22
24	HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nature Reviews Clinical Oncology, 2016, 13, 119-132.	27.6	154
25	Potential impact of a 9-valent HPV vaccine in HPV-related cervical disease in 4 emerging countries (Brazil, Mexico, India and China). Cancer Epidemiology, 2014, 38, 748-756.	1.9	37
26	HPV in genital cancers (at the exception of cervical cancer) and anal cancers. Presse Medicale, 2014, 43, e423-e428.	1.9	48
27	Burden of Human Papillomavirus Infections and Related Diseases in the Extended Middle East and North Africa Region. Vaccine, 2013, 31, G32-G44.	3.8	36
28	Using HPV prevalence to predict cervical cancer incidence. International Journal of Cancer, 2013, 132, 1895-1900.	5.1	26
29	Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infectious Agents and Cancer, 2012, 7, 38.	2.6	232
30	The Epidemiology of Cervical Cancer. , 2012, , 63-83.		3
31	Global Burden of Human Papillomavirus and Related Diseases. Vaccine, 2012, 30, F12-F23.	3.8	1,254
32	Human papillomavirus types in 115,789 HPVâ€positive women: A metaâ€analysis from cervical infection to cancer. International Journal of Cancer, 2012, 131, 2349-2359.	5.1	706
33	Cervical Human Papillomavirus Prevalence in 5 Continents: Metaâ€Analysis of 1 Million Women with Normal Cytological Findings. Journal of Infectious Diseases, 2010, 202, 1789-1799.	4.0	1,156
34	Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infectious Diseases, The, 2007, 7, 453-459.	9.1	1,277